TrianglePembrolizumab (NCT05188508)
Pembrolizumab trial for Glioma (NCT05188508). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with recurrent grade II–III IDH-mutant glioma without known CDKN2A/B deletion, or recurrent IDH-wildtype glioma with a qualifying DNA-repair-gene mutation. Prior-treatment requirements differ by cohort.
The idea: pembrolizumab releases an immune brake, olaparib blocks DNA repair, and temozolomide damages DNA. Pembrolizumab infusions start alone; oral olaparib and temozolomide join during cycles three through eleven. Pembrolizumab maintenance continues, up to thirty-five cycles. Researchers assess response and safety.
This phase 2 study plans 57 patients. Lauren Schaff leads at Memorial Sloan Kettering, New York; ten US locations are listed as recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.